NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

October 12, 2015

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

October 08, 2015

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.

October 07, 2015

Protein engineering expert Shohei Koide, PhD, appointed Director of Cancer Biologics at Perlmutter Cancer Center to lead groundbreaking new initiative in growing field of research and therapeutics

October 02, 2015

Anna C. Ferrari, MD, professor, co-director, GU Research Program, Departments of Medicine (Cancer Center) and Medicine (Residency Program), discusses a study that examined the efficacy of LBH589 and bicalutamide in patients with castration-resistant prostate cancer.

September 25, 2015

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

September 10, 2015

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

September 09, 2015

Jeffrey S. Weber, MD, PhD, to serve as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone, Co-Director of its Melanoma Program and Head of Experimental Therapeutics.

August 31, 2015

Anna Pavlick, DO, discusses immunotherapy and targeted combination regimens in advanced melanoma.

August 10, 2015

Andrew S. Chi, MD, PhD, has also been appointed co-director of the NYU Langone Brain Tumor Center.

July 24, 2015

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

July 14, 2015

Melissa A. Wilson, MD, PhD, discusses how targeted therapies and combination protocols are revolutionizing the treatment paradigm of advanced melanoma.

June 30, 2015

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

June 22, 2015

Francisco J. Esteva, MD, PhD, professor, Department of Medicine, associate director, Clinical Investigation Perlmutter Cancer Center, director, Breast Medical Oncology Program, NYU Langone Medical Center, discusses the efficacy of T-DM1 in patients with HER2-positive breast cancer.

March 31, 2015

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).

March 22, 2015

Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.

February 23, 2015

A joint program at the NYU Langone Medical Center and the Technion-Israel Institute of Technology is positioned to attract additional, world-class support from institutions and individuals who are dedicated to eradicating cancer through focused and efficient research.

December 20, 2014

The use of multiparametric MRI in diagnosing and treating prostate cancer was explored in November during a continuing medical education course offered at the annual meeting of LUGPA

December 17, 2014

When added to standard chemotherapy, trastuzumab not only dramatically improved disease-free survival rates for patients with metastatic disease, but also resulted in a clear survival advantage unprecedented for most treatments of metastatic breast cancer.

October 31, 2014

Internationally renowned cancer biologist Benjamin G. Neel, MD, PhD, an expert in the field of cell signal transduction, has been named Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center – a National Cancer Institute-designated cancer center.

October 31, 2014

Researchers analyzed artwork, advertisements and leisure time activities to estimate historic changes in UV exposure